Incyte公司的培美替尼在哪买？

It is a small molecule kinase inhibitor targeting FGFR1, 2 and 3 with an IC50 value of less than 2nM. Pemetinib also inhibits FGFR4 in vitro at approximately 100-fold higher concentrations than FGFR1, 2, and 3. Pemetinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability. So, where can I buy Incyte’s pemetinib?

According to Medical Companion Travel, we have learned that the price of pemetinib is not fixed due to exchange rate fluctuations. For specific prices, you can consult the Medical Companion Travel Service. Patients in need can purchase the drug abroad or obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel), and have it shipped directly to their homes to ensure authenticity.

American Genetic Engineering Technology Company, referred to as Genentech, is the oldest biotechnology company in the United States and the second largest biotechnology company in the world after Amgen in terms of scale and strength. In order to achieve the goal of becoming the world's largest oncology pharmaceutical company, Genentech suspended research on the long-acting recombinant human growth hormone Nutroppin Deptot and focused on the research and development of oncology drugs such as Avastin. Genentech is the earliest biotechnology pharmaceutical company established and the first to develop biotechnology drugs.

According to data from a study, the intrahepatic cholangiocarcinoma-targeted drug pemetinib can achieve an objective response rate of 35.5% and a disease control rate of 82% in the treatment of patients with cholangiocarcinoma. The median duration of response was 9.1 months, with as many as 63% of patients having a response duration of ≥6 months and 18% of patients with a duration of ≥12 months.

It is not difficult to see from these data that targeted drugs have a very significant effect on disease control and prognosis improvement of intrahepatic cholangiocarcinoma. The advent of the targeted drug pemetinib is good news for many patients with intrahepatic cholangiocarcinoma. This drug has changed the current treatment status of intrahepatic cholangiocarcinoma and provided doctors and patients with a new diagnosis and treatment plan.

Recommended related hot articles: /newsDetail/96505.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.